Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

B. Douglas Smith, MD, Gail J. Roboz, MD, Roland B. Walter, MD PhD, Jessica K. Altman, MD, Anna Ferguson, BSN, RN, Tania J. Curcio, R.N, Kaysey F. Orlowski, Linda Garrett, RN, Samantha J Busfield, PhD, Megan Barnden, PhD, Brad Sedgmen, PhD, Souravi Ghosh, PhD, Sarah Hosback, PhD, Roslyn Davis, MSc, Allison Dyson, BSc, Sue Dasen, MS, Mark DeWitte, VMD, Debra M. Bensen-Kennedy, MD, Andrew W. Roberts, MBBS, PhD

Blood (2014) 124 (21): 120.

https://doi.org/10.1182/blood.V124.21.120.120

Published: 2014

Journal Articles

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Ellen K. Ritchie, MD, Danielle C. Marshall, B.A., Molly D. Greenberg, B.S., Tania J. Curcio, R.N, Ashley E. Giambrone, PhD, Paul Christos, DrPH, Eric J. Feldman, MD, Joseph M. Scandura, MD PhD, Gail J. Roboz, MD

Blood (2014) 124 (21): 3689.

https://doi.org/10.1182/blood.V124.21.3689.3689

Published: 2014

Journal Articles

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Usama Gergis, MD, Gail J. Roboz, MD, Ellen Ritchie, MD, Joseph M. Scandura, MD, PhD, Karen-Sue B. Carlson, MD, PhD, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, June Greenberg, Tania J Curcio, R.N, Cindy Ippoliti, PharmD, Marshall McKenna, Eric J Feldman, MD

Blood (2011) 118 (21): 3030.

https://doi.org/10.1182/blood.V118.21.3030.3030

Published: 2011

Journal Articles

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

Joseph M. Scandura, Gail J. Roboz, Michelle Moh, Ewelina Morawa, Fabienne Brenet, J. Robi Bose, Luis Villegas, Usama S. Gergis, Sebastian A. Mayer, Cindy M. Ippoliti, Tania J. Curcio, Ellen K. Ritchie, Eric J. Feldman

Blood (2011) 118 (6): 1472–1480.

https://doi.org/10.1182/blood-2010-11-320093

Published: 2011

Includes: Supplemental data

Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Eric J. Feldman, MD, Jeffrey Lancet, MD, Jonathan E. Kolitz, MD, Ellen Ritchie, MD, Alan F. List, MD, Ekatherine Asatiani, MD, Tania J Curcio, Michelle Burton, RN, Marge Fricano, BSN, Christine Swenson, Lawrence D Mayer, PhD, Arthur C. Louie, MD

Blood (2008) 112 (11): 2984.

https://doi.org/10.1182/blood.V112.11.2984.2984

Published: 2008

Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ekatherine Asatiani, Tania J. Curcio, Michelle K. Burton, Marjorie Fricano, Amanda R. Begley, Christine Swenson, Lawrence Mayer, Andrew S. Janoff, Arthur C. Louie

Blood (2007) 110 (11): 900.

https://doi.org/10.1182/blood.V110.11.900.900

Published: 2007

Journal Articles

Arsenic Trioxide (ATO) Is Safe and Effective in Combination with Low-Dose Ara-C (LDAC) for the Treatment of IPSS-2 Myelodysplastic Syndrome (MDS) and Poor-Prognosis Acute Myeloid Leukemia (AML) in Elderly Patients.

Gail J. Roboz, MD, Ellen K. Ritchie, MD, Sandra Allen-Bard, N.P., Tania J. Curcio, R.N., Juliette L. Provenzano, MS, Michael S. Samuel, BA, Michael W. Schuster, MD, Alison W. Bloch, BA, Eric J. Feldman, MD

Blood (2005) 106 (11): 2805.

https://doi.org/10.1182/blood.V106.11.2805.2805

Published: 2005

Journal Articles

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Gail J. Roboz, MD, Ellen K. Ritchie, MD, Michael W. Schuster, MD, Tsiporah Shore, MD, Tania J. Curcio, R.N., Sandra Allen-Bard, N.P., Juliette L. Provenzano, MS, Eric J. Feldman, MD

Blood (2005) 106 (11): 1856.

https://doi.org/10.1182/blood.V106.11.1856.1856

Published: 2005

NARROW

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

Arsenic Trioxide (ATO) Is Safe and Effective in Combination with Low-Dose Ara-C (LDAC) for the Treatment of IPSS-2 Myelodysplastic Syndrome (MDS) and Poor-Prognosis Acute Myeloid Leukemia (AML) in Elderly Patients.

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only